정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1780 | Active, not recruiting | COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection | Coronavirus | Biological: ChAdOx1 nCoV-19 Biological: Normal saline 0.9% |
Phase 2 | University of Oxford, Medical Research Council, South Africa, Bill and Melinda Gates Foundation, Wits Health Consortium (Pty) Ltd, University of Witwatersrand, South Africa | OTHER | 2130 | All | 18 Years ~ 65 Years | PHRU Kliptown, Johannesburg, Gauteng, South Africa Soweto Clinical Trials Centre, Johannesburg, Gauteng, South Africa Wits RHI Shandukani Research Centre, Johannesburg, Gauteng, South Africa Setshaba Research Centre (SRC), Soshanguve, Gauteng, South Africa Chris Hani Baragwanath Academic Hospital - DST/NRF VPD RMPRU, Soweto, Gauteng, South Africa FAMCRU, Cape Town, Western Cape, South Africa Groote Schuur hospital, Lung infection and immunity unit, UCT, Cape Town, Western Cape, South Africa |
| 1779 | Recruiting | COVID-19 Vaccine Boosters in Patients With CKD | COVID-19 | Biological: Pfizer-BioNTech COVID-19 Vaccine Biological: MODERNA SARS-CoV-2 Vaccine |
Phase 3 | Sunnybrook Health Sciences Centre, Sunnybrook Health Sciences Center, University Health Network, Toronto, Unity Health Toronto, Scarborough General Hospital, Providence Healthcare | OTHER | 300 | All | 18 Years | Sunnybrook Health Science Center, Toronto, Ontario, Canada |
| 1778 | Withdrawn | COVID-19 Vaccine For Indirect Protection | Vaccine Preventable Disease | Biological: COVID-19 Vaccination Other: Usual care |
Phase 4 | McMaster University, University of Alberta, University of Saskatchewan, University of Manitoba | OTHER | 0 | All | McMaster University, Hamilton, Ontario, Canada | |
| 1777 | Active, not recruiting | COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases | SLE | Biological: Moderna COVID-19 vaccine | Phase 3 | McGill University Health Centre/Research Institute of the McGill University Health Centre, CHU de Quebec-Universite Laval, Ministere de la Sante et des Services Sociaux | OTHER | 220 | All | 18 Years | McGill University Health Centre, Montreal, Quebec, Canada |
| 1776 | Not yet recruiting | COVID-19 VaccinE Response in Rheumatology Patients | Spondylarthritis | Drug: Upadacitinib Drug: Abatacept Drug: Secukinumab Drug: Tofacitinib Drug: TNF Inhibitor Drug: Canakinumab Injection |
Phase 4 | Jeffrey Curtis, University of Alabama at Birmingham, University of Nebraska, University of Pennsylvania, AbbVie, Bristol-Myers Squibb, Novartis, Eli Lilly and Company, Pfizer | OTHER | 1000 | All | 18 Years ~ 85 Years | University of Alabama at Birmingham, Birmingham, Alabama, United States University of Nebraska Medical Center, Omaha, Nebraska, United States |
| 1775 | Recruiting | COVID-19 Vaccines in Patients With Chronic Liver Disease | Liver Disease Chronic | Biological: COVID-19 Vaccines | Not Applicable | Beijing 302 Hospital | OTHER | 300 | All | 18 Years | The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China |
| 1774 | Recruiting | COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies | Chronic Lymphocytic Leukemia | Drug: A single "booster" dose of the Moderna mRNA COVID-19 vaccine | Phase 2 | Barbara Ann Karmanos Cancer Institute | OTHER | 171 | All | 18 Years | Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States |